and timelines.

2. Scope

This SOP applies to all personnel involved in the development of sterile injectable products, from pre-formulation through formulation, analytical method development, scale-up, process validation, and technology transfer stages. It encompasses both technical and regulatory risks associated with APIs, excipients, container-closure systems, processing technologies, and equipment.

3. Responsibilities

• Formulation Scientists: Identify technical risks associated with APIs, excipients, and formulation processes.
• Analytical Development Team: Highlight risks related to analytical method development, sensitivity, and validation.
• Project Managers: Monitor timelines and regulatory risks during development phases.
• Quality Assurance (QA): Ensure compliance with QRM principles and verify documentation integrity.
• Risk Management Team: Facilitate risk review meetings, document risk registers, and coordinate mitigation plans.

4. Accountability

The Head of Formulation Development is accountable for the implementation and maintenance of risk management strategies throughout the lifecycle. QA Head is accountable for oversight and audit readiness of risk documentation.

5. Procedure

5.1 Risk Identification

1. During project initiation, conduct brainstorming sessions with cross-functional teams to list all known and potential risks.
2. Sources of risk include:
   • API characteristics (e.g., poor solubility, instability)
   • Excipient interaction risks
   • Sterility challenges
   • Analytical method limitations
   • Container-closure compatibility
   • Equipment capability and scale-up risk
   • Regulatory expectations (ICH, WHO, FDA)
3. Record all identified risks in the Risk Register (Annexure-1).

5.2 Risk Analysis

1. Each risk shall be analyzed for:
   • Severity (S): Impact on product quality or patient safety
   • Occurrence (O): Likelihood of risk materializing
   • Detection (D): Ability to detect the risk before product release
2. Use a risk matrix scoring method:
   • Scale: 1 (Low) to 5 (High)
   • Calculate Risk Priority Number (RPN): RPN = S × O × D
3. Document RPNs in the Risk Assessment Log (Annexure-2).

5.3 Risk Evaluation

1. Classify risks based on RPN values:
   • Low Risk: RPN ≤ 40
   • Medium Risk: RPN = 41–80
   • High Risk: RPN ≥ 81
2. High risks must be immediately escalated and mitigation plans initiated.

5.4 Risk Control

1. For all risks with RPN > 40, define and implement risk reduction strategies:
   • Change in formulation strategy
   • Redesign of analytical methods
   • Procurement of alternate excipients
   • Redundancy in sterility assurance
2. Assign risk owners to track implementation and outcomes.
3. Update risk control status in Annexure-3: Risk Mitigation Tracker.

5.5 Risk Review and Monitoring

1. Conduct formal risk review meetings during major development milestones:
   • Post-formulation optimization
   • Pre-technology transfer
   • Pre-validation
2. Review effectiveness of implemented controls by evaluating updated RPNs.
3. Maintain records in Risk Review Summary Report (Annexure-4).

5.6 Risk Communication

1. Communicate critical risks and controls to all stakeholders including QA, RA, and Production.
2. Include risk management summary in regulatory submissions such as CTD Module 3.2.R.

5.7 Risk Documentation and Retention

1. Ensure all risk-related documents are controlled under the Document Management System (DMS).
2. Maintain electronic and hard copies for a minimum of five years post product discontinuation.

6. Abbreviations

• API: Active Pharmaceutical Ingredient
• QA: Quality Assurance
• QRM: Quality Risk Management
• RPN: Risk Priority Number
• CTD: Common Technical Document

7. Documents

1. Risk Register – Annexure-1
2. Risk Assessment Log – Annexure-2
3. Risk Mitigation Tracker – Annexure-3
4. Risk Review Summary Report – Annexure-4

8. References

• ICH Q9: Quality Risk Management
• ICH Q8(R2): Pharmaceutical Development
• FDA Guidance on Quality Risk Management, 2006

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Executive	Head QA
Department	Formulation Development	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Risk Register

Risk ID	Description	Source	Date Identified
R001	API solubility issue	Pre-formulation study	05/05/2025

Annexure-2: Risk Assessment Log

Risk ID	Severity	Occurrence	Detection	RPN
R001	5	4	3	60

Annexure-3: Risk Mitigation Tracker

Risk ID	Mitigation Action	Owner	Status
R001	Use of solubility enhancer	Sunita Reddy	Completed

Annexure-4: Risk Review Summary Report

Review Date	Reviewed By	Key Updates	Follow-Up Required
01/06/2025	Rajesh Kumar	RPN reduced to 30	No

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
20/06/2022	1.0	Initial SOP	New Product Lifecycle Risk SOP	Head QA
24/06/2025	2.0	Expanded procedure and annexures	Annual review and enhancement	Head QA